Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第10页

Monetary valuation of one year in full capability and health based on demographics, health status, income and well-being. 根据人口统计、健康状况、收入和福祉，对一年的完全能力和健康进行货币估值。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-24 DOI: 10.1080/14737167.2024.2347647

M. Thema, Z. Beretzky, V. Brodszky

{"title":"Monetary valuation of one year in full capability and health based on demographics, health status, income and well-being.","authors":"M. Thema, Z. Beretzky, V. Brodszky","doi":"10.1080/14737167.2024.2347647","DOIUrl":"https://doi.org/10.1080/14737167.2024.2347647","url":null,"abstract":"BACKGROUND\u0000Budget constraints in health care systems have led to the popularity of Cost Effectiveness Thresholds (CET) to achieve efficient allocation of resources. The capability approach has been hailed for its potentially richer evaluative capabilities compared to the QALY in terms of thresholds. Extensive research, however, is still limited.\u0000\u0000\u0000RESEARCH DESIGN AND METHODS\u0000This study estimated the monetary value of a year in full capability (YFC) and compared it to monetary value of a QALY for the Hungarian population. Data was collected from a large, cross sectional, representative online survey on the adult Hungarian population. Applying the wellbeing valuation method, health, capability, and income were then regressed against wellbeing to estimate 'shadow prices' for one QALY and YFC controlling for gender, age, employment, education, marital and social support. To examine 'core' regression coefficients, a robustness check was conducted.\u0000\u0000\u0000RESULTS\u0000Health (VAS) and capability (ICECAP-A) had a positive and significant effect on Subjective Well-Being. The monetary values of one QALY and one YFC were 39 459 EUR and 58 148 EUR respectively.\u0000\u0000\u0000CONCLUSIONS\u0000These tools provide a systematic approach to determining 'compensating income' for certain illnesses, disabilities and levels of pain. The capability approach shown to be broader than the QALY.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140661574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China 中国晚期胃癌或胃食管交界处癌一线治疗中辛替利单抗加化疗与化疗的成本效益比较

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-09 DOI: 10.1080/14737167.2024.2341859

Wei Li, Li Wan

引用次数: 0

Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023 药物经济学和结果研究专家评论：2023 年的高影响力文章

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-09 DOI: 10.1080/14737167.2024.2339945

Mickaël Hiligsmann, Mitchell P. DeKoven, Riddhi Doshi, Carolyn Gotay, Carlo Lazzaro, Jayashri Sankaranarayanan, Rayya Hajjar

引用次数: 0

Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control 秘鲁 2 型糖尿病的经济负担：一项疾病成本研究，评估与血糖控制水平相关的成本差异

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-08 DOI: 10.1080/14737167.2024.2333337

Janice Seinfeld, Alfredo Sobrevilla, María Laura Rosales, Mauricio Ibáñez, Delia Ruiz, Eduardo Penny, Sergio Londoño

引用次数: 0

The impact of bone turnover marker on medication adherence and the health economics-related consequences 骨转换标志物对坚持用药的影响以及与健康经济相关的后果

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-03 DOI: 10.1080/14737167.2024.2337718

Nannan Li, Niklas Rye Jørgensen, Jean-Yves Reginster, Mickaël Hiligsmann

引用次数: 0

Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment. 在欧洲充分利用生物仿制药的整体效益--第二部分：付款人如何保障未来健康的生物仿制药市场环境。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-01 Epub Date: 2024-02-12 DOI: 10.1080/14737167.2024.2310684

Jorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, Paul Cornes, Matti S Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer, Arnold G Vulto

{"title":"Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.","authors":"Jorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, Paul Cornes, Matti S Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer, Arnold G Vulto","doi":"10.1080/14737167.2024.2310684","DOIUrl":"10.1080/14737167.2024.2310684","url":null,"abstract":"Introduction: Biosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets.Areas covered: An expert panel of eight diverse European stakeholders provided insights about rethinking biosimilars and cost-savings, reducing patient access inequalities, increasing inter-market equity, and improving education. The insights reported here (Part 2) follow a study that provides perspectives on leveraging the holistic benefits of biosimilars for market sustainability based on independent survey results and telephone interviews of stakeholders from diverse biosimilar markets (Part 1). Directional recommendations are provided for payers.Expert opinion: The panel's market maturity framework for biosimilars has three stages: 'Invest,' 'Expand' and 'Harvest.' Across market stages, re-thinking the benefits of biosimilars beyond cost-savings, considering earlier or expanded access/new indications, product innovations, and re-investment of biosimilar-generated cost-savings should be communicated to stakeholders to promote further engagement. During 'Expand' and 'Harvest' stages, development of efficient, forward-looking procurement systems and mechanisms that drive uptake and stabilize competition between manufacturers are key. Future biosimilars will target various therapy areas beyond those targeted by existing biosimilars. To ensure a healthy, accessible future market, stakeholders must align their objectives, communicate, collaborate, and coordinate via education, incentivization, and procurement, to maximize the totality of benefits.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation. 综合卫生经济评估报告标准 2022（CHEERS II）声明：经过验证的荷兰语译文。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1080/14737167.2024.2324048

Amber Werbrouck, Esther de Bekker-Grob, Maiwenn Al, Koen Putman, Ruben Willems

{"title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation.","authors":"Amber Werbrouck, Esther de Bekker-Grob, Maiwenn Al, Koen Putman, Ruben Willems","doi":"10.1080/14737167.2024.2324048","DOIUrl":"10.1080/14737167.2024.2324048","url":null,"abstract":"Objectives: This study primarily aimed to develop a validated Dutch translation of the 28 items of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) II. A secondary aim was to provide a worked example of a scientifically valid translation process.Methods: A four-step process was applied: (1) forward translation, (2) backward translation, (3) quantitative validation (two back-translated English versions vs. original English version), and (4) qualitative validation (one Dutch version vs. original English version), resulting in the final Dutch CHEERS II checklist.Results: During quantitative validation, the average scores indicated high language comparability (1.88 (SD 0.70); 1.70 (SD 0.73)) and interpretation similarity (1.77 (SD 0.81); 1.54 (SD 0.74)). Four items required formal revision. In the qualitative validation step, feedback primarily focused on specific terms 'outcomes,' 'benefits and harms,' '(year of) conversion,' 'any,' and 'characterizing.'Conclusion: Despite English being the common language of science, translating research instruments remains relevant to enhance clarity, accessibility, and inclusivity. The Dutch translation can be used by students, regulators, researchers, or others to report and evaluate reporting of economic evaluations. Our detailed description of the applied methodology can facilitate future translations of research instruments.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data. 急性髓性白血病对患者和护理人员缺勤的影响急性髓性白血病患者和护理人员的缺勤、残疾和工资损失：利用美国行政索赔和生产力数据进行的队列研究。

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-01 Epub Date: 2024-02-26 DOI: 10.1080/14737167.2024.2311305

Bhavik J Pandya, Christopher Young, Elizabeth R Packnett, Bin Xie, Timothy Lillehaugen, Alana Block, Katarzyna Bernacki, Maelys Touya, Thomas W LeBlanc

{"title":"Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data.","authors":"Bhavik J Pandya, Christopher Young, Elizabeth R Packnett, Bin Xie, Timothy Lillehaugen, Alana Block, Katarzyna Bernacki, Maelys Touya, Thomas W LeBlanc","doi":"10.1080/14737167.2024.2311305","DOIUrl":"10.1080/14737167.2024.2311305","url":null,"abstract":"Objective: We describe the impact of acute myeloid leukemia (AML) diagnosis on workplace absenteeism and disability days among patients and their caregivers.Methods: This retrospective study included adults with newly diagnosed AML (2009-2019) and adult caregivers of patients with newly diagnosed AML, identified from the US Merative™ MarketScan® Commercial Database. The Merative MarketScan Health and Productivity Management Database provided linked patient-level records of workplace absence and short-term (STD) and long-term disability (LTD) data. Endpoints included workplace absence, STD and LTD for patients and caregivers during 12 months pre-AML (baseline) and ≤3 years' follow-up, and corresponding cost of work loss.Results: Patient workplace absence decreased in the months post-AML diagnosis, but the number of STD and LTD leave days claimed increased significantly by sixfold and fourfold, respectively. The proportion of patients making STD leave claims increased within 4-5 months of diagnosis, while the proportion making LTD leave claims increased significantly starting from month 5. Caregiver workplace absence peaked in the first 2 months post-diagnosis and remained elevated versus baseline throughout the study.Conclusion: AML diagnosis leads to workplace absenteeism and increased economic burden for patients with AML and their caregivers.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation instruments for executive functions in children and adolescents: an update of a systematic review. 儿童和青少年执行功能评估工具：系统综述。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-01 Epub Date: 2024-02-06 DOI: 10.1080/14737167.2024.2311872

Arianna Cesari, Giovanni Galeoto, Francescaroberta Panuccio, Rachele Simeon, Anna Berardi

{"title":"Evaluation instruments for executive functions in children and adolescents: an update of a systematic review.","authors":"Arianna Cesari, Giovanni Galeoto, Francescaroberta Panuccio, Rachele Simeon, Anna Berardi","doi":"10.1080/14737167.2024.2311872","DOIUrl":"10.1080/14737167.2024.2311872","url":null,"abstract":"Introduction: The aim of this study is to update a systematic review of instruments for evaluating the executive functions (EFs) in a pediatric population to assess their measurement properties.Area covered: Studies describing evaluation tools of EFs were systematically searched on four electronic databases: PubMed, EBSCO, Scopus, and Web of Science. To be included studies had to be on a population aged 0 to 18 were included. The individuals were either healthy or presented a neurodevelopment disorder. Risk of Bias was evaluated through the Consensus-based Standards to select the health Measurement Instruments (COSMIN).Expert opinion: The search was conducted on April 2023. Eighty-four papers met the inclusion criteria and were included in the study; the studies refer to 72 different evaluation tools of EFs. Most of the studies analyzed through a methodological quality analysis received an 'adequate' score. The instrument most mentioned was the Behavior Rating Inventory of Executive Function-2 (BRIEF2) in seven articles.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug pricing and transparency in Europe and the United States: what is it and how does it work? 欧洲和美国的药品定价和透明度：它是什么，如何发挥作用？

IF 2.3 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI: 10.1080/14737167.2024.2311302

Steven Simoens, Mondher Toumi

{"title":"Drug pricing and transparency in Europe and the United States: what is it and how does it work?","authors":"Steven Simoens, Mondher Toumi","doi":"10.1080/14737167.2024.2311302","DOIUrl":"10.1080/14737167.2024.2311302","url":null,"abstract":"Introduction: As drug prices are viewed to be opaque, there have been increasing societal demands on policy and decision makers to implement initiatives that promote drug price transparency.Areas covered: This Perspective discusses what drug price transparency is and how it works in theory and in practice.Expert opinion: Transparency on drug prices may target payers, patients and health care professionals; and may relate to prices at each stage in a drug's distribution system. Although proponents claim that drug price transparency will reduce prices and increase patient access, others expect the opposite effect. Nevertheless, a number of international organizations, countries and consumer groups have taken steps to enhance drug price transparency. This has occurred despite a lack of theoretical clarity and of evidence about its likely impact. Policy and decision makers need to consider how payers and pharmaceutical companies are likely to react to drug price transparency and need to be aware that transparency may produce different effects depending on the country to which it is applied. Even though we believe that full drug price transparency is elusive, various incremental measures can be taken to move toward it.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0